PT  - JOURNAL ARTICLE
AU  - Folco, Cécile Di
AU  - Jabouley, Aude
AU  - Reyes, Sonia
AU  - Machado, Carla
AU  - Guey, Stéphanie
AU  - Hervé, Dominique
AU  - Fernandes, Fanny
AU  - Agossa, Joseph
AU  - Chabriat, Hugues
AU  - Tezenas du Montcel, Sophie
TI  - CADA-PRO, a patient questionnaire measuring key cognitive, motor, emotional and behavioral Outcomes in CADASIL
AID  - 10.1101/2024.05.30.24306664
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.05.30.24306664
4099  - http://medrxiv.org/content/early/2024/05/31/2024.05.30.24306664.short
4100  - http://medrxiv.org/content/early/2024/05/31/2024.05.30.24306664.full
AB  - Background Cerebral Small Vessel Disease (cSVD) of ischemic type, either sporadic or genetic, as Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), can impact the quality of daily life on various cognitive, motor, emotional or behavioral aspects. No instrument has been developed to measure these outcomes from the patient’s perspective. We thus aimed to develop and validate a patient-reported questionnaire.Methods In a development study, 79 items were generated by consensus between patients, family representatives and cSVD experts. A first sample of patients allowed assessing the feasibility (missing data, floor and ceiling effect, acceptability), internal consistency, and dimensionality of a first set of items. Thereafter, in a validation study, we tested a reduced version of the item set in a larger sample to assess the feasibility, internal consistency, dimensionality, test-retest reliability, concurrent validity, and sensitivity to change.Results The scale was developed in 44 cSVD patients and validated in a second sample of 89 individuals (including 43 patients with CADASIL and 46 with another cSVD). The final CADASIL Patient-Reported Outcome (CADA-PRO) scale comprised 18 items covering four categories of consequences (depression/anxiety, attention/executive functions, motor, daily activities) of the disease. The proportion of missing data was low, no item displayed major floor or ceiling effect. Both the internal consistency and test-retest reliability were good (Cronbach alpha = 0.95, intraclass correlation coefficient = 0.88). In patients with CADASIL, CADA-PRO scores correlated with the modified Rankin scale, Starkstein Apathy Scale (SAS), Hospital Anxiety and Depression scale (HAD), and Trail Making Test times. In patients with other cSVDs, CADA-PRO correlated only with HAD and SAS.Conclusion The CADA-PRO is an innovative instrument for measuring patient-reported outcomes in future cSVD trials. Full validation was obtained for its use in CADASIL patients, but further improvement is needed for its application in other cSVDs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was mainly supported by the ANR grant RHU TRT—cSVD (ANR:16-RHUS-0004) and a grant from H2020 EJPRD - CADANHIS. The study was also done with the help of the Association ARNEVA (Association de Recherche en Neurologie Vasculaire).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Informed consent was obtained from each subject or a close relative if necessary. Data were collected through the SMACS study, which was approved by the Comité de Protection des Personnes Ile de France IV (2019-A01892-55).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymized data not published within this article will be made available upon request from any qualified investigator.CADASILcerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathycSVDcerebral Small Vessel DiseaseEFExecutive FunctionsEFAExploratory Factor AnalysisFCSRTFree and Cued Selective Reminding TestHADHospital Anxiety and Depression scaleMIRTConfirmatory Multidimensional Item Response TheorymRSmodified Rankin scalePGICPatient Global Impression of ChangeSASStarkstein Apathy ScaleSSPB - 4Short Physical Performance Battery (4 items)TMTTrail Making TestVADAS-CogVascular Dementia Assessment Scale cognitive subscaleSDMTSymbol-Digit Modalities TestWCSTWisconsin Card Sorting TestWMS-IIIWeschler Memory Scale 3rd revision